The ASCO 2018 annual meeting: update on the adjuvant treatment of early breast cancer
- 39 Downloads
At this year’s American Society of Clinical Oncology (ASCO) annual meeting two large phase 3 trials, the ABCSG-18 and the D‑CARE study, analysed the effects of adjuvant denosumab in breast cancer patients and reported different outcomes. Another phase 3 study, the ASTRRA trial, investigated the use of adjuvant ovarian function suppression (OFS) in high-risk premenopausal patients. This trial confirmed the benefit of OFS similar to the results of the already published SOFT/TEXT trials but raises some crucial questions on the optimal duration of OFS in these patients. The results of the SOFT/TEXT trials were also updated at this meeting.
KeywordsBisphosphonates Endocrine therapy Bone-modifying agents Denosumab Ovarian function suppression
Conflict of interest
C. Dormann and K.J. Aichberger declare that they have no competing interests.
- 2.Dhesy-Thind S, Fletcher GG, Blanchette PS, et al. Use of Adjuvant Bisphosphonates and other Bone-modifying agents in breast cancer: a cancer care ontario and American society of clinical oncology clinical practice guideline. J Clin Oncol. 2017;35(18):2062–81. https://doi.org/10.1200/JCO.2016.70.7257.CrossRefPubMedGoogle Scholar
- 4.Coleman RE, Finkelstein D, Barrios CH, et al. Adjuvant denosumab in early breast cancer: first results from the international multicenter randomized phase III placebo controlled D‑CARE study. J Clin Oncol. 2018;36(15_suppl):501–501. https://doi.org/10.1200/JCO.2018.36.15_suppl.501.CrossRefGoogle Scholar
- 8.Regan MM, Francis PA, Pagani O, et al. Absolute benefit of Adjuvant endocrine therapies for Premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2‑negative early breast cancer: TEXT and SOFT trials. J Clin Oncol. 2016;34:2221–31. https://doi.org/10.1200/JCO.2015.64.3171.CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Regan MM, Francis PA, Pagani O, et al. Absolute improvements in freedom from distant recurrence with adjuvant endocrine therapies for premenopausal women with hormone receptor-positive (HR+) her2-negative breast cancer (BC): results from TEXT and SOFT. J Clin Oncol. 2018;36(15_suppl):503–503. https://doi.org/10.1200/JCO.2018.36.15_suppl.503.CrossRefGoogle Scholar
- 11.Noh WC, Lee JW, Nam SJ, et al. Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: the ASTRRA study. J Clin Oncol. 2018;36(15_suppl):502–502. https://doi.org/10.1200/JCO.2018.36.15_suppl.502.CrossRefGoogle Scholar